Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand

Abramova, Olga B.; Kaplan, M. A.; Grin, Mikhail A.; Suvorov, Nikita; Миронов, А. Ф.; Drozhzhina, V. V.; Churikova, T. P.; Kozlovtseva, E. A.; Bandurko, L.N.; Yakovleva, N. D.; Иванов, С. А.; Каприн, А. Д.

doi:10.1007/s10517-021-05252-x

Cited by 7 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mironov [ 5 ]. The high efficiency of the PDT with this PS on prostate tumor cells (22Rv1) has been shown previously [ 6 ]. In our previously published work, the high photoinduced activity of this PS against B16 melanoma tumor cells was revealed [ 6 ].…”

Section: Introductionsupporting

confidence: 57%

“…The high efficiency of the PDT with this PS on prostate tumor cells (22Rv1) has been shown previously [ 6 ]. In our previously published work, the high photoinduced activity of this PS against B16 melanoma tumor cells was revealed [ 6 ]. The studies conducted so far have shown that laser exposure in the 45–60 mins after the intravenous administration of PS at a dose of 2.5–5.0 mg/kg with light exposure parameters E = 144 J/cm 2 , Ps = 0.48 W/cm 2 causes 100% eradication of tumor nodules and the absence of their recurrence over 3 months of observation.…”

Section: Introductionsupporting

confidence: 57%

“…The studies conducted so far have shown that laser exposure in the 45–60 mins after the intravenous administration of PS at a dose of 2.5–5.0 mg/kg with light exposure parameters E = 144 J/cm 2 , Ps = 0.48 W/cm 2 causes 100% eradication of tumor nodules and the absence of their recurrence over 3 months of observation. Presumably, this result was achieved due to the high selectivity of PS accumulation in the tumor caused by PSMA ligand uptake by PSMA receptors in mouse melanoma cells [ 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

On the Pathomorphological Pattern of the Efficiency of Photodynamic Therapy of Murine Melanoma B16 Using a New Photosensitizer Based on Chlorin e6 Conjugate with a Prostate-Specific Membrane Antigen

et al. 2022

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an effective treatment for a number of solid malignancies. In this work, the antitumor efficacy of photodynamic therapy for murine B16 melanoma with intravenous administration of a new photosensitizer (PS) based on the chlorin e6 conjugate with a prostate-specific membrane antigen (PSMA) was studied in vivo. We have previously published the data obtained in the first part of the study: the dynamics of PS accumulation in the tumor and surrounding tissues and the antitumor efficacy of the photodynamic therapy, which was evaluated by the regression parameters and morphological characteristics of the tumors—including by the complete regression of the tumors, the absolute growth rate of the tumors among the mice with continued tumor growth, and an increase in life expectancy compared to the control. The criterion for a complete cure was the absence of signs of tumor recurrence within 90 days after therapy. The conducted studies demonstrated the high efficiency of the new photosensitizer for the photodynamic therapy of B16 melanoma. This article presents a continuation of this work, including histological studies of the zones exposed to laser irradiation on the 21st day after treatment and an assessment of the therapeutic potential of photodynamic therapy for the destruction of tumor cells. Pathological studies in the zones of photodynamic exposure revealed that the effectiveness of the PDT depended on the PS dose and the laser irradiation parameters.

show abstract

Section: Introductionsupporting

confidence: 57%

Section: Introductionsupporting

confidence: 57%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

On the Pathomorphological Pattern of the Efficiency of Photodynamic Therapy of Murine Melanoma B16 Using a New Photosensitizer Based on Chlorin e6 Conjugate with a Prostate-Specific Membrane Antigen

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We ranked the pathways based on the

( Yue et al, 2019a ). As reported the highest PubMed score in Table 2 , the photodynamic therapy has been frequently reported for melanoma treatment in recent years ( Shivashankarappa and Sanjay, 2019 ; Turkoglu et al, 2019 ; Abramova et al, 2021 ; Yordi et al, 2021 ). We observed that in the overlapped genes between differentially expressed gene candidates and the photodynamic therapy-induced ap-1 survival signaling’s gene members, the five genes, IL6 (Interleukin 6), CDKN1A (Cyclin Dependent Kinase Inhibitor 1A), FGF7 (Fibroblast Growth Factor 7), BCL3 (B-Cell Lymphoma 3-Encoded Protein) and PDGFRA (Platelet Derived Growth Factor Receptor Alpha) were under-expressed in the drug-resistant patients, and the three genes, IL6, CDKN1A and FGF7 were connected in the gene regulatory network from PAGER ( de Waal Malefyt et al, 1991 ) ( Figure 4 ).…”

Section: Resultsmentioning

confidence: 99%

PAGER Web APP: An Interactive, Online Gene Set and Network Interpretation Tool for Functional Genomics

et al. 2022

View full text Add to dashboard Cite

Functional genomics studies have helped researchers annotate differentially expressed gene lists, extract gene expression signatures, and identify biological pathways from omics profiling experiments conducted on biological samples. The current geneset, network, and pathway analysis (GNPA) web servers, e.g., DAVID, EnrichR, WebGestaltR, or PAGER, do not allow automated integrative functional genomic downstream analysis. In this study, we developed a new web-based interactive application, “PAGER Web APP”, which supports online R scripting of integrative GNPA. In a case study of melanoma drug resistance, we showed that the new PAGER Web APP enabled us to discover highly relevant pathways and network modules, leading to novel biological insights. We also compared PAGER Web APP’s pathway analysis results retrieved among PAGER, EnrichR, and WebGestaltR to show its advantages in integrative GNPA. The interactive online web APP is publicly accessible from the link, https://aimed-lab.shinyapps.io/PAGERwebapp/.

show abstract

“…As photodynamic therapy (PDT) has been developed since the 1980s, many other treatment options have been improved. PDT has proven useful for many types of tumors, such as melanoma [ 1 , 2 ], esophageal cancer [ 3 , 4 ], and multidrug-resistant lung and breast cancers [ 5 , 6 ]. After other oncology applications, interest in PDT as a high-grade glioma treatment stems from both the nature of tumor growth and the limited effectiveness of modern therapies available to this patient population [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Kim

Lee

2022

Biomedicines

View full text Add to dashboard Cite

The current treatment for malignant brain tumors includes surgical resection, radiotherapy, and chemotherapy. Nevertheless, the survival rate for patients with glioblastoma multiforme (GBM) with a high grade of malignancy is less than one year. From a clinical point of view, effective treatment of GBM is limited by several challenges. First, the anatomical complexity of the brain influences the extent of resection because a fine balance must be struck between maximal removal of malignant tissue and minimal surgical risk. Second, the central nervous system has a distinct microenvironment that is protected by the blood–brain barrier, restricting systemically delivered drugs from accessing the brain. Additionally, GBM is characterized by high intra-tumor and inter-tumor heterogeneity at cellular and histological levels. This peculiarity of GBM-constituent tissues induces different responses to therapeutic agents, leading to failure of targeted therapies. Unlike surgical resection and radiotherapy, photodynamic therapy (PDT) can treat micro-invasive areas while protecting sensitive brain regions. PDT involves photoactivation of photosensitizers (PSs) that are selectively incorporated into tumor cells. Photo-irradiation activates the PS by transfer of energy, resulting in production of reactive oxygen species to induce cell death. Clinical outcomes of PDT-treated GBM can be advanced in terms of nanomedicine. This review discusses clinical PDT applications of nanomedicine for the treatment of GBM.

show abstract

Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand

Cited by 7 publications

References 7 publications

On the Pathomorphological Pattern of the Efficiency of Photodynamic Therapy of Murine Melanoma B16 Using a New Photosensitizer Based on Chlorin e6 Conjugate with a Prostate-Specific Membrane Antigen

On the Pathomorphological Pattern of the Efficiency of Photodynamic Therapy of Murine Melanoma B16 Using a New Photosensitizer Based on Chlorin e6 Conjugate with a Prostate-Specific Membrane Antigen

PAGER Web APP: An Interactive, Online Gene Set and Network Interpretation Tool for Functional Genomics

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Contact Info

Product

Resources

About